J&J Submits Dapoxetine NDA For Premature Ejaculation

The company is waiting to see if the selective serotonin reuptake inhibitor will receive priority review. Submission is slightly earlier than expected.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet